# Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma

> **NCT01844401** · PHASE1 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Albuterol Spiromax®
- **DRUG:** ProAir® HFA

## Key facts

- **NCT ID:** NCT01844401
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2013-08
- **Final completion:** 2013-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844401, "Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01844401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*